Aripiprazole Oral Acceptability Trial
Information source: Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Schizophrenia
Intervention: Aripiprazole (Drug); Aripiprazole (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Otsuka Pharmaceutical Development & Commercialization, Inc. Official(s) and/or principal investigator(s): Bristol-Myers Squibb, Study Director, Affiliation: Bristol-Myers Squibb
Summary
The purpose of this trial is to study liquid aripiprazole in patients with stable
schizophrenia.
Clinical Details
Official title: Aripiprazole Oral Acceptability Trial
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: acceptability
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Stable patients currently receiving aripiprazole or other antipsychotic medications.
Locations and Contacts
Local Institution, Anaheim, California, United States
Local Institution, National City, California, United States
Local Institution, North Miami Beach, Florida, United States
Local Institution, Overland Park, Kansas, United States
Local Institution, Staten Island, New York, United States
Local Institution, Oklahoma City, Oklahoma, United States
Local Institution, Falls Church, Virginia, United States
Additional Information
BMS Clinical Trials Disclosure For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm
Starting date: March 2004
Last updated: November 7, 2013
|